🇺🇸 FDA
Pipeline program

RBD7022

RBD7022

Phase 1 small_molecule completed

Quick answer

RBD7022 for Hyperlipemia is a Phase 1 program (small_molecule) at Suzhou Ribo Life Science Co. with 1 ClinicalTrials.gov record(s).

Program details

Company
Suzhou Ribo Life Science Co.
Indication
Hyperlipemia
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials